Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759
RDN
0.007
75%
HMD
0.012
-36.8%
XAM
0.079
54.9%
ERA
0.002
-33.3%
NSX
0.033
50%
EIQ
0.24
-25%
ROG
0.005
25%
ICR
0.006
-25%
LDR
0.16
23.1%
MMR
0.003
-25%
MGA
0.061
22%
AZL
0.007
-22.2%
FRS
0.075
21%
ATX
0.051
-21.5%
OD6
0.03
20%
C1X
0.055
-21.4%
AM5
0.013
18.2%
TEM
0.004
-20%
BLU
0.007
16.7%
HCT
0.045
-19.6%
CLA
0.007
16.7%
ANR
0.005
-16.7%
CTQ
0.014
16.7%
AQX
0.005
-16.7%
HOR
0.021
16.7%
EMU
0.02
-16.7%
M24
0.014
16.7%
MEM
0.005
-16.7%
SPX
0.007
16.7%
RC1
0.005
-16.7%
OFX
1.315
16.4%
T92
0.025
-16.7%
OSX
0.015
15.4%
LTR
0.68
-16.6%
EXR
0.031
14.8%
ORD
0.39
-16.1%
EOS
1.48
14.7%
APX
1.23
-15.8%
AHF
0.047
14.6%
IVX
0.081
-14.7%
